ALS Patient-Led Research Initiative
Amyotrophic Lateral Sclerosis
Key Facts
About BGI
BGI Genomics, founded in 2006 and headquartered in Copenhagen, Denmark, is a global leader in providing integrated genomic sequencing and multi-omics solutions for precision medicine. The company operates a worldwide network of service labs, offering sequencing, mass spectrometry, and data analysis services primarily to the research, clinical, and public health sectors. Its business model is focused on diagnostic services and research partnerships, positioning it as a key infrastructure player in the genomics ecosystem rather than a traditional therapeutic developer. Recent initiatives highlight its work in areas like colorectal cancer microbiome analysis, rare diseases like ALS, and international government partnerships.
View full company profileOther Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Research | GliaPharm | Research |
| ALS Disease Model Service | NeuroProof | Pre-clinical |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| ALS Program | Biorchestra | Preclinical |
| Program(s) for ALS | AviadoBio | Pre-clinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ILB® for ALS | TikoMed | Phase 2 |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |